UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pathophysiological role of endothelin in acute renal failure

Life sciences (1973), 1990, Vol.46 (22), p.1611-1618

1990

Volltextzugriff (PDF)

Novel Non-Peptide Fibrinogen Receptor Antagonists. 1. Synthesis and Glycoprotein IIb-IIIa Antagonistic Activities of 1,3,4-Trisubstituted 2-Oxopiperazine Derivatives Incorporating Side-Chain Functions of the RGDF Peptide

Journal of medicinal chemistry, 1998-02, Vol.41 (4), p.489-502

1998

Volltextzugriff (PDF)

Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents

The Journal of pharmacology and experimental therapeutics, 1992-02, Vol.260 (2), p.748

1992

Volltextzugriff (PDF)

Potent Dibasic GPIIb/IIIa Antagonists with Reduced Prolongation of Bleeding Time: Synthesis and Pharmacological Evaluation of 2-Oxopiperazine Derivatives

Journal of medicinal chemistry, 2001-07, Vol.44 (15), p.2438-2450

2001

Volltextzugriff (PDF)

TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats

The Journal of pharmacology and experimental therapeutics, 1993-09, Vol.266 (3), p.1664

1993

Volltextzugriff (PDF)

Orally Active GPIIb/IIIa Antagonists: Synthesis and Biological Activities of Masked Amidines as Prodrugs of 2-[(3S)-4-[(2S)-2-(4-Amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid

Chemical and Pharmaceutical Bulletin, 2001, Vol.49(3), pp.268-277

2001

Volltextzugriff (PDF)

Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia

The Journal of pharmacology and experimental therapeutics, 1988-03, Vol.244 (3), p.898

1988

Volltextzugriff (PDF)

Novel Non-Peptide GPIIb/IIIa Antagonists: Synthesis and Biological Activities of 2-[4-[2-(4-Amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acids

Chemical and Pharmaceutical Bulletin, 2001, Vol.49(3), pp.258-267

2001

Volltextzugriff (PDF)

CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo

The Journal of pharmacology and experimental therapeutics, 1987-07, Vol.242 (1), p.263

1987

Volltextzugriff (PDF)

A lethal role of platelet activating factor in anaphylactic shock in mice

The Journal of pharmacology and experimental therapeutics, 1987-10, Vol.243 (1), p.378

1987

Volltextzugriff (PDF)

Inhibition by CV-3988 of the binding of [ 3H]-platelet activating factor (PAF) to the platelet

Biochemical pharmacology, 1985-05, Vol.34 (9), p.1491-1495

1985

Volltextzugriff (PDF)

Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban

The Journal of pharmacology and experimental therapeutics, 1996-04, Vol.277 (1), p.502

1996

Volltextzugriff (PDF)

EFFECTS OF TAK-029, A NOVEL GPIIb/IIIa ANTAGONIST, ON ARTERIAL THROMBOSIS IN GUINEA PIGS, DOGS AND MONKEYS

Thrombosis research, 1997-05, Vol.86 (4), p.275-285

1997

Volltextzugriff (PDF)

Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells

Biochemical pharmacology, 1990-12, Vol.40 (12), p.2713-2717

1990

Volltextzugriff (PDF)

Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids

Journal of medicinal chemistry, 1985-03, Vol.28 (3), p.287-294

1985

Volltextzugriff (PDF)

Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model

Thrombosis research, 1995-07, Vol.79 (1), p.95-107

1995

Volltextzugriff (PDF)

Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury

Thrombosis research, 1995-03, Vol.77 (5), p.411-421

1995

Volltextzugriff (PDF)

Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation

Thrombosis research, 1993-05, Vol.70 (4), p.281-293

1993

Volltextzugriff (PDF)

Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives

Journal of medicinal chemistry, 1992-06, Vol.35 (12), p.2202-2209

1992

Volltextzugriff (PDF)

Antihypertensive and Cardiovascular Effects of a New Potassium Channel Opener, TCV-295, in Rats and Dogs

Journal of cardiovascular pharmacology, 1994-12, Vol.24 (6), p.929-936

1994

Volltextzugriff (PDF)

The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage

Thrombosis research, 1990-07, Vol.59 (1), p.195-205

1990

Volltextzugriff (PDF)

Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats

Kidney international, 1991-05, Vol.39 (5), p.920-929

1991

Volltextzugriff (PDF)

Stereoselective Synthesis and Thromboxane A2 (TXA2) Receptor Antagonistic Activity of Optically Active Phenol Derivatives

Chemical and Pharmaceutical Bulletin, 1996/04/15, Vol.44(4), pp.749-755

1996

Volltextzugriff (PDF)

Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of Trisubstituted Piperazine Derivatives

Chemical and Pharmaceutical Bulletin, 1994/03/15, Vol.42(3), pp.551-559

1994

Volltextzugriff (PDF)

Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of 1, 4-Disubstituted Piperazine Derivatives

Chemical and Pharmaceutical Bulletin, 1994/03/15, Vol.42(3), pp.541-550

1994

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(94)
Tagungsberichte
(2)

Sprache

Englisch
(94)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pathophysiological role of endothelin in acute renal failure

Novel Non-Peptide Fibrinogen Receptor Antagonists. 1. Synthesis and Glycoprotein IIb-IIIa Antagonistic Activities of 1,3,4-Trisubstituted 2-Oxopiperazine Derivatives Incorporating Side-Chain Functions of the RGDF Peptide

Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents

Potent Dibasic GPIIb/IIIa Antagonists with Reduced Prolongation of Bleeding Time: Synthesis and Pharmacological Evaluation of 2-Oxopiperazine Derivatives

TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats

Orally Active GPIIb/IIIa Antagonists: Synthesis and Biological Activities of Masked Amidines as Prodrugs of 2-[(3S)-4-[(2S)-2-(4-Amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid

Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia

Novel Non-Peptide GPIIb/IIIa Antagonists: Synthesis and Biological Activities of 2-[4-[2-(4-Amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acids

CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo

A lethal role of platelet activating factor in anaphylactic shock in mice

Inhibition by CV-3988 of the binding of [ 3H]-platelet activating factor (PAF) to the platelet

Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban

EFFECTS OF TAK-029, A NOVEL GPIIb/IIIa ANTAGONIST, ON ARTERIAL THROMBOSIS IN GUINEA PIGS, DOGS AND MONKEYS

Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells

Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids

Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model

Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury

Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation

Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives

Antihypertensive and Cardiovascular Effects of a New Potassium Channel Opener, TCV-295, in Rats and Dogs

The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage

Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats

Stereoselective Synthesis and Thromboxane A2 (TXA2) Receptor Antagonistic Activity of Optically Active Phenol Derivatives

Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of Trisubstituted Piperazine Derivatives

Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of 1, 4-Disubstituted Piperazine Derivatives

Suchergebnisse filtern